Stuart A Arbuckle Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Stuart A Arbuckle is EVP, COO of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 62,935 shares of VRTX, which is worth approximately $30.2 Million. The most recent transaction as insider was on Feb 26, 2025, when has been sold 7,071 shares (Common Stock) at a price of $479.61 per share, resulting in proceeds of $3,391,322. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.9K

26.65% 3M change

26.65% 12M change

Total Value Held $30.2 Million

Stuart A Arbuckle Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 26 2025	SELL Payment of exercise price or tax liability	$3,391,322 $479.61 p/Share	7,071 Reduced 10.1%	62,935 Common Stock
Feb 24 2025	SELL Payment of exercise price or tax liability	$2,279,148 $483.28 p/Share	4,716 Reduced 6.31%	70,006 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$1,262,465 $463.46 p/Share	2,724 Reduced 3.52%	74,722 Common Stock
Feb 12 2025	BUY Grant, award, or other acquisition	-	7,903 Added 9.26%	77,446 Common Stock
Feb 10 2025	SELL Payment of exercise price or tax liability	$1,506,895 $467.98 p/Share	3,220 Reduced 4.43%	69,543 Common Stock
Feb 04 2025	BUY Grant, award, or other acquisition	-	23,072 Added 24.07%	72,763 Common Stock
May 15 2024	SELL Open market or private sale	$29,734 $430.93 p/Share	69 Reduced 0.14%	49,691 Common Stock
Feb 26 2024	SELL Open market or private sale	$2,142,973 $425.7 p/Share	5,034 Reduced 9.2%	49,691 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$2,035,458 $431.79 p/Share	4,714 Reduced 7.93%	54,725 Common Stock
Feb 21 2024	SELL Open market or private sale	$1,519,637 $421.77 p/Share	3,603 Reduced 5.72%	59,439 Common Stock
Feb 20 2024	SELL Open market or private sale	$2,021,475 $420.79 p/Share	4,804 Reduced 7.08%	63,042 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$1,418,616 $420.58 p/Share	3,373 Reduced 4.74%	67,846 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$1,907,620 $424.01 p/Share	4,499 Reduced 5.94%	71,219 Common Stock
Feb 12 2024	SELL Open market or private sale	$1,804,930 $420.24 p/Share	4,295 Reduced 5.37%	75,718 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$1,343,044 $422.74 p/Share	3,177 Reduced 3.82%	80,013 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	8,448 Added 9.22%	83,190 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	18,186 Added 19.57%	74,742 Common Stock
Dec 13 2023	SELL Open market or private sale	$3,432,597 $399.0 p/Share	8,603 Reduced 13.2%	56,556 Common Stock
Dec 13 2023	BUY Exercise of conversion of derivative security	$1,613,320 $187.53 p/Share	8,603 Added 11.66%	65,159 Common Stock
Jun 15 2023	SELL Open market or private sale	$3,002,447 $349.0 p/Share	8,603 Reduced 13.2%	56,556 Common Stock
Jun 15 2023	BUY Exercise of conversion of derivative security	$1,613,320 $187.53 p/Share	8,603 Added 11.66%	65,159 Common Stock
May 30 2023	SELL Open market or private sale	$27,045 $329.82 p/Share	82 Reduced 0.14%	56,556 Common Stock
Feb 27 2023	SELL Open market or private sale	$1,449,238 $287.89 p/Share	5,034 Reduced 8.17%	56,556 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$1,362,911 $289.12 p/Share	4,714 Reduced 7.11%	61,590 Common Stock
Feb 22 2023	SELL Open market or private sale	$706,230 $294.14 p/Share	2,401 Reduced 3.49%	66,304 Common Stock

Also insider at

RYTM

RHYTHM PHARMACEUTICALS, INC. Healthcare

Director

IMGN

ImmunoGen, Inc. Healthcare

Director

SAA